Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Consulting agrmnt
Quarterly results
Inv. presentation
Director departure
|
|
Augmedix, Inc. (AUGX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/07/2023 |
8-K
| Quarterly results|
Docs:
|
"Augmedix Delivers 47% Revenue Growth and Expanded Gross Margins for Second Quarter of 2023 SAN FRANCISCO, August 7, 2023 – Augmedix , a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions to healthcare systems, physician practices, hospitals, and telemedicine practitioners, today reported financial results for the three and six months ended June 30, 2023. “This was another strong quarter for Augmedix, as we continue to solidify our position within the burgeoning ambient medical documentation market,” commented Manny Krakaris, Chief Executive Officer at Augmedix. “We set records for revenue, growing 47% year-over-year, and dollar-based net revenue retention at 148%, demonstrating that health systems and clinicians increasingly value ..." |
|
| 05/12/2023 |
8-K
| Investor presentation, Quarterly results |
| 03/27/2023 |
8-K
| Quarterly results|
Docs:
|
"Augmedix Reports Strong Commercial Traction and Sales Momentum; Reports Fourth Quarter and Full Year 2022 Financial Results SAN FRANCISCO, Calif. –– March 27, 2023 –– Augmedix , a leading provider of ambient medical documentation and data solutions delivered remotely to healthcare systems, physician practices, hospitals, and telemedicine practitioners, today reported financial results for the three and 12 months ended December 31, 2022. “We finished 2022 with our best-ever fourth quarter in terms of bookings, with sales momentum continuing into 2023 with record first-quarter bookings, including our largest-ever clinician cohort signed,” said Manny Krakaris, Chief Executive Officer at Augmedix. “Our expanding portfolio of products has positioned us well for the large market opportunity in f..." |
|
| 11/14/2022 |
8-K
| Quarterly results |
| 08/08/2022 |
8-K
| Investor presentation, Quarterly results |
| 05/09/2022 |
8-K
| Quarterly results |
| 03/21/2022 |
8-K
| Quarterly results|
Docs:
|
"Augmedix Reports Fourth Quarter and Full Year 2021 Financial Results SAN FRANCISCO, Calif. –– Augmedix, Inc. , a leading provider of automated medical documentation and data services, today reported financial results for the three months ended December 31, 2021. “We are pleased with the progress we made in 2021, as we continued to execute well across our strategic initiatives and finished the year by delivering our strongest quarter to date,” said Manny Krakaris, Chief Executive Officer at Augmedix. “The fourth quarter was highlighted by our accelerated revenue growth, gross margin expansion, and meaningful progress along our path to a fully-automated medical note. Our highly differentiated approach to the medical note creation process has positioned us well for the large market opportunit..." |
|
| 11/09/2021 |
8-K
| Quarterly results |
| 11/17/2020 |
8-K
| Quarterly results|
Docs:
|
"Augmedix, Inc. Condensed Consolidated Statement of Operations Unaudited Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Revenue $ 4,245,256 $ 3,668,466 $ 11,940,407 $ 10,150,048 Cost of revenue 2,368,542 2,340,432 7,153,228 6,832,388 Gross margin 1,876,714 1,328,034 4,787,179 3,317,660 General and administrative 3,336,512 2,594,327 8,480,410 8,257,287 Sales and marketing 886,738 1,000,499 2,945,161 2,634,205 Research and development 1,008,594 1,950,835 3,484,833 5,182,308 Total operating expenses 5,231,844 5,545,661 14,910,404 16,073,800 Operating loss Other income , net Net loss $ $ $ $ Reconciliation of Non-GAAP Metrics Net loss $ $ $ $ Interest 401,546 1,479,073 1,197,150 2,379,486 Tax 25,720 27,809 98,918 72,028 Depreciation 213,302 234,020 645,..." |
|
|
|